Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference 1H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives

Chemical and Pharmaceutical Bulletin

Volumn 60, Issue 1, 2012, Pages 70-78

  Mohebbi, Shohreh ^a   Falcón Pérez, Juan Manuel ^b   González, Esperanza ^b   Millet, Oscar ^c   Mato, Jose Maria ^b   Kobarfard, Farzad ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CIC BIOGUNE   (Spain)

Author keywords

Diaminopyrimidine; Dihydrofolate reductase inhibitory activity; Synthesis

Indexed keywords

2 (2 CHLOROBENZYLTHIO)PYRIMIDINE 4,6 DIAMINE; 2 (2 FLUOROBENZYLTHIO)PYRIMIDINE 4,6 DIAMINE; 2 (2 METHYLBENZYLTHIO)PYRIMIDINE 4,6 DIAMINE; 2 (3 FLUOROBENZYLTHIO)PYRIMIDINE 4,6 DIAMINE; 2 (PHENYLETHYLTHIO)PYRIMIDINE 4,6 DIAMINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HELA CELLS; HEP G2 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84855930064     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.60.70     Document Type: Article

References (16)

1. Jackson R. C., "Antifolate Drugs in Cancer Therapy," ed. by Jackman A. L., Humana Press, Totowa, 1999, pp. 1-12.
2. Berman E. M., Werbel L. M., J. Med. Chem., 34, 479-485 (1991).
3. MacKenzie R. E., "Folates and Pterins," 2nd ed., Vol. 1, ed. by Blakley R. L., Benkovic S. J., Wiley-Interscience, New York, 1984, pp. 255-306.
4. Suckling C. J., "Enzyme Chemistry," Chapman and Hall Ltd., New York, 1984, p. 121.
5. Peters G. J., Kohne C. H., "Antifolate Drugs in Cancer Therapy,"ed. by Jackson A. L., 1999, pp. 101-145.
6. Jackman A. L., Boyle F. T., Harrap K. R., Invest. New Drugs, 14, 305-316 (1996).
7. Takimoto C. H., Semin Oncol., S18-40-S18-51 (1997).
8. Jordell D. I., Bowman A., Rye R., Byrne B., Boddy A., Rafi I., Taylor G. A., Johnston A., Clendeninn N. J., Br. J. Cancer, 79, 915-920 (1999).
9. Yamini L., Vijjulatha M., E-Journal of Chemistry, 5, 263-270 (2008).
10. Crepaldi P., Cacciari B., Bonache M. C., Spalluto G., Varani K. P. A., Borea P. A., Kügelgen I., Hoffmann K., Pugliano M., Razzari C., Cattaneo M., Bioorg. Med. Chem., 17, 4612-4621 (2009).
11. Krishnan V. V. Current, Anal. Chem., 2005, 1-49 (2005).
12. Cody V., Galitsky N., Luft J. R., Pangborn W., Rosowsky A., Blakley R. L., Biochemistry, 36, 13897-13903 (1997).
13. Rosowsky A., "Progress in Medicinal Chemistry," ed. by Ellis G. P., West G. B., Elsevier Science Publishers, Amsterdam, 1989, pp. 1-252.
14. Gangjee A., Elzein E., Kothare M., Vasudevan A., Curr. Pharm. Des., 2, 263-280 (1996).
15. Gangjee A., Yu J., McGuire J. J., Cody V., Galitsky N., Kisliuk R. L., Queener S. F., J. Med. Chem., 43, 3837-3851 (2000).
16. Franken N. A. P., Rodermond H. M., Stap J., Haveman J., van Bree C., Nat. Protoc., 1, 2315-2319 (2006).